Obesity drugs may be pricey, but they’re also cost-effective, analysis finds

Taking stock of the drug industry, from the lab to the medicine chest

September 9, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Scott Olson/Getty Images STAT+ | Obesity drugs may be pricey, but they're also cost-effective, analysis finds The price tags charged by both manufacturers would have to greatly exceed existing prices before ICER would determine the value is inadequate. By Ed Silverman STAT+ | Dozens of lawmakers urge HHS to abandon a pilot initiative for the controversial 340B program At issue is the 340B discount program, which was created to help hospitals and clinics care for low-income and rural patients. By Ed Silverman STAT+ | An API supplier in India wants you to know its metal detector is working just fine The warning from the FDA highlights ongoing anxiety over quality control among pharmaceutical companies in India. By Ed Silverman Anna Yeo/STAT STAT+ | Novartis to buy Tourmaline Bio, gaining promising heart medicine The centerpiece of the deal is pacibekitug, which mid-stage trial data showed could successfully lower heart inflammation. By Andrew Joseph STAT+ | Lilly will let small biotechs use its AI models at no cost Lilly launches TuneLab to make its proprietary artificial intelligence models available at no cost to selected biotechs By Brittany Trang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser